Quest for the right Drug
לויטרה 10 מ"ג LEVITRA ® 10 MG (VARDENAFIL AS HYDROCHLORIDE TRIHYDRATE)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
פומי : PER OS
צורת מינון:
טבליות מצופות פילם : FILM COATED TABLETS
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8 Undesirable effects Summary of the safety profile The adverse reactions reported with Levitra film-coated tablets or 10 mg orodispersible tablets in clinical trials were generally transient and mild to moderate in nature. The most commonly reported adverse drug reaction occurring in ≥ 10% of patients is headache. Tabulated list of adverse reactions Adverse reactions are listed according to the MedDRA frequency convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000) and not known (can not be estimated from available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. The following adverse reactions have been reported: System Organ Very Common Uncommon Rare Not known Class common (≥1/100 to (≥1/1,000 to (≥1/10,000 to (cannot be (≥1/10) <1/10) <1/100) <1/1,000) estimated from the available data) Infection and Conjunctivitis infestations Immune system Allergic oedema Allergic reaction disorders and angioedema Psychiatric Sleep disorder Anxiety disorders Nervous system Headache Dizziness Somnolence Syncope Cerebral haemorrhage disorders Paraesthesia and Seizure dysaesthesia Amnesia Transient ischaemic attack Eye disorders Visual disturbance Increase in intraocular Non-arteritic anterior Ocular hyperaemia pressure ischemic optic Visual colour Lacrimation increased neuropathy distortions Visual defects Eye pain and eye discomfort Photophobia Ear and Tinnitus Sudden deafness labyrinth Vertigo disorders Cardiac Palpitation Myocardial infarction Sudden death disorders Tachycardia Ventricular tachy- arrhythmias Angina pectoris Vascular Flushing Hypotension disorders Hypertension Respiratory, Nasal Dyspnoea Epistaxis thoracic and congestion Sinus congestion mediastinal disorders Gastrointestinal Dyspepsia Gastro- disorders oesophageal reflux disease Gastritis Gastrointestinal and abdominal pain Diarrhoea Vomiting Nausea Dry mouth Hepatobiliary Increase in Increase in gamma- disorders transaminases glutamyl transferase Skin and Erythema Photosensitivity reaction subcutaneous Rash tissue disorders System Organ Very Common Uncommon Rare Not known Class common (≥1/100 to (≥1/1,000 to (≥1/10,000 to (cannot be (≥1/10) <1/10) <1/100) <1/1,000) estimated from the available data) Musculoskeletal Back pain and connective Increase in creatine tissue disorders phosphokinase Myalgia Increased muscle tone and cramping Renal and Haematuria urinary disorders Reproductive Increase in erection Priapism Penile Haemorrhage system and Haematospermia breast disorders General Feeling unwell Chest pain disorders and administration site conditions Description of selected adverse reactions Penile haemorrhage, haematospermia and haematuria have been reported in clinical trials and spontaneous post-marketing data with the use of all PDE5 inhibitors, including vardenafil. At a dose of 20 mg Levitra film-coated tablets, elderly (≥65 years old) patients had higher frequencies of headaches (16.2% versus 11.8%) and dizziness (3.7% versus 0.7%) than younger patients (<65 years old). In general, the incidence of adverse reactions (especially “dizziness”) has been shown to be slightly higher in patients with a history of hypertension. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form https://sideeffects.health.gov.il/
פרטי מסגרת הכללה בסל
התרופה האמורה תינתן לטיפול באין אונות בהשתתפות עצמית של עד 100%.לעניין התכשירים Sildenafil, Tadalafil, Vardenafil לטיפול באין אונות הקופה תהיה רשאית לגבות השתתפות עצמית עד 100% מהמחיר המרבי לצרכן, והשתתפות עצמית זו לא תיכלל בחישוב התקרה לחולים כרוניים.
מסגרת הכללה בסל
התוויות הכלולות במסגרת הסל
התוויה | תאריך הכללה | תחום קליני | Class Effect | מצב מחלה |
---|---|---|---|---|
לטיפול באין אונות | 15/01/2015 | אורולוגיה | SILDENAFIL, TADALAFIL, VARDENAFIL |
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
15/01/2015
הגבלות
תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת
מידע נוסף